Cure Alzheimer's Fund Cure Alzheimer's Fund

Novel Soluable Gamma-Secretase Modulators

2010

Building on in vitro characterization of a novel series of soluable gamma-secretase modulators (SGSMs) funded by Cure Alzheimer’s Fund, the current project is a thorough pharmacological or in vivo examination of these molecules to identify the best or “lead” drug candidate.

Drug Development Preclinical Drug Development Rudy Tanzi Steven L. Wagner

Funding to Date

$250,000

Focus

Drug Development, Preclinical Drug Development

Researchers

Steven L. Wagner, Ph.D.

Rudy Tanzi, Ph.D.

Related Content:


Sex-biased Toll-Like Receptor 7 (TLR7) Signaling in Demyelination and its Inhibition by Small Molecules Li Gan Subhash Sinha 2024-11-23 Combined Hormone Therapy as a Novel Treatment for Alzheimer’s Disease in the Face of a Metabolic Challenge: Influence of Sex and Genotype Liisa Galea Annie Ciernia 2024-08-19 Non-Invasive Delivery of IL-2 to the CNS for Local Expansion of Regulatory T Cells and Prevention of Neurodegeneration in Tauopathy Peter M. Tessier David Holtzman 2024-06-26 Preclinical Analysis of Synaptogyrin-3 Oligonucleotides to Target Tauopathy Patrik Verstreken 2024-03-18 Microbiome Consortium: Microbial Profiling of Human Brain and Gut Microbiomes in Alzheimer’s Disease Rudy Tanzi Nanda Kumar Navalpur Shanmugam 2023-11-02 Role of Stabilization of MAMs and MAM-Associated Palmitoylated APP (MAM-palAPP) in Alzheimer’s Disease Raja Bhattacharyya 2023-11-02 Targeting Neuroinflammation with Nasal Administration of Anti-CD3 Monoclonal Antibody to Treat Alzheimer’s Disease Rafael M. Rezende 2023-10-25 Role of CD8+ T-Cell-Glial Interactions in Mediating Alzheimer’s Disease Pathogenesis Mehdi Jorfi Joseph Park Rudy Tanzi 2023-09-19